ABOUT
Company
A company dedicated to fostering the health and wellness of its customers.
Located within the Daejeon Daedeok Industrial Complex, our Daejeon factory stands as a beacon of high-quality pharmaceutical production.
It has proven its caliber by successfully navigating Japan’s PMDA inspections in 2014 and 2018. Beyond its own product lineup, the factory reliably caters to several other pharmaceutical firms.
The Daejeon factory, inaugurated in 1992, has set a benchmark in global finished pharmaceutical production standards. Over the years, our dedication to consistent facility upgrades, process improvements, and rigorous quality control has earned us excellence certifications from various domestic and international regulatory bodies.
Each year, the Daejeon factory manufactures 600 million tablets, 300 million capsules, and approximately 2 million bottles of syrup. This vast production not only meets our internal requirements but also supplies a plethora of other pharmaceutical companies.
Our integrated pharmaceutical production line spans from the initial research phase right through to final production. Built on robust manufacturing management and stringent quality control, we’ve secured accolades such as the Korean MFDS GMP certification and twice passed the rigorous Japan PMDA inspections in 2014 and 2018.
From a technological perspective, we take pride in our Western-style micro-particle coating techniques and our unique bitter taste masking capability. With an arsenal of fluid bed granulators, we excel in crafting superior special formulations. On the equipment front, we harness the power of cutting-edge bitter taste masking syrup technology, allowing us to cater to modern packaging needs, including 500 mL bottles and the trending stick packaging line. Our packaging spectrum spans from PTP systems to carton packaging, anchored by an automated PTP line that boasts an advanced inspection mechanism.
The Daejeon factory encapsulates unparalleled technical proficiency, streamlined manufacturing, and testing protocols, and a refined production environment. With our eyes set on the horizon and backed by continuous investments and procedural enhancements, we are a beacon of progressive evolution.
Serving as the backbone of Kolon Pharma, the factory plays a pivotal role in translating the company’s ambitious vision and values. As we stride forward, we envision ourselves as a pioneering global pharma-bio entity.
The Daejeon Medical Research Institute channels its efforts to uphold patient-centric values, consistently producing pharmaceutical solutions. Our mission revolves around bolstering our pipeline with unique offerings such as first generics, refined drugs, and breakthrough pharmaceuticals.
Our research ethos is grounded in strategically identifying lucrative research prospects, adhering religiously to development schedules, and fortifying our approach with global accreditation standards, ensuring we’re always ahead of the curve.
Beyond current endeavors, our sight is set on amplifying future values. A testament to this is our resolute focus on expanding the R&D pipeline and scouting for transformative technologies through open innovation (Platform Technology).
The Kolon Pharma Medical Research Institute is the culmination of integrated systems, well-equipped to oversee a spectrum of tasks: from research planning, process development, and analytical method creation to process research, scale-up processes, analytical validation, and CTD documentation for regulatory approval.
